Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

DNA topoisomerases are essential nuclear enzymes involved in multiple nuclear functions such as chromosomal recombination, DNA repair, transcription and chromatin assembly (Eng et al, 1988; Hsiang et al, 1989). Topoisomerase I and II inhibitors are of great clinical interest because of their important antitumour activity in a broad spectrum of tumour types (Rothenberg, 1997). The expression of topoisomerase I and IIβ does not vary significantly during the cell cycle, whereas topoisomerase IIα expression increases during the S phase and reaches a peak at G2/M phase (Heck et al, 1988). It has been shown in preclinical studies that crossresistance between topoisomerase I and II inhibitors is unusual in resistant cell lines (Ferguson et al, 1988). Alterations in the regulation of one topoisomerase are often compensated by alterations in the other (LeFevre et al, 1991). Joint inhibitors of topoisomerase I and II appear to combine the properties of the individual specific inhibitors but act across the cell cycle, and so target a larger population of cells in any asynchronous population, resulting in greater antitumour activity. Several of these ‘dual inhibitors’ have been identified, including intoplicin, saintopin, XR5000 and F11782 (Newman et al, 1999; Twelve et al, 1999; Etievant et al, 2000; Denny and Baguley, 2003).

4-methoxy-benzo[a]phenazine-11-carboxylic acid (2-dimethylamino-1-R-methyl-ethyl)-amide (XR11576) is a novel substituted benzo[a]phenazine-11-carboxamide that targets both topoisomerase I and II (Figure 1) (Jobson et al, 2002; Wang et al, 2002).

In vitro, XR11576 exerted antitumour activity against a variety of murine and human tumour cell lines, including rapidly proliferating murine leukaemias and human colon, breast, ovarian and lung carcinoma cell lines. In vivo, XR11576 was highly active against human colon and small-cell lung cancer xenografts (Mistry et al, 2002; Lewis et al, 2003). XR11576 was also active against multidrug-resistant cells overexpressing P-gp or MRP, or against cells with downregulation of topoisomerase II levels (Di Nicolantonio et al, 2002). On giving XR11576 orally to rodents and dogs, its antitumour activity was preserved.

In animals, XR11576 predominantly induced bone marrow and gastrointestinal toxicity. In addition, when i.v. doses were repeatedly administered to dogs, myocarditis and nephritis were
observed. However, these toxicities were not observed in studies of repeated oral dosing. Furthermore, no cardiac toxicity was detected in a cardiovascular safety study (data on file, FPD 1055). The maximum tolerated doses (MTDs) in a 14-day oral administration schedule in rats and 8/9-day oral administration schedule in dogs were 150 and 200 mg m$^{-2}$, respectively. The oral route of administration was chosen because the i.v. route induced unacceptable vein irritation and because XR11576 had proven activity when given orally, which would enable a more convenient method of prolonged drug administration and create the opportunity for cost-effective outpatient therapy.

The pharmacokinetics (PKs) of XR11576 have been studied in several animal species. After single intravenous administration, XR11576 rapidly distributed from plasma into the tissues, resulting in a large volume of distribution. After both i.v. and oral administration to mice and rats, high tissue levels of XR11576 relative to plasma were observed, with the highest and most prolonged drug levels in tumour tissue. The oral availabilities of XR11576 in mice and rats were 72 ± 25 and 54 ± 32%, respectively. In mice, food reduced the bioavailability. After single oral administration to dogs, the systemic exposure increased more than dose-proportionally. The unchanged drug was the major component in plasma. However, there was evidence of hepatic metabolism to at least one major metabolite. Plasma half-life varied between 1 and 9 h. Repeated daily oral doses in dogs did result in a reduction in the systemic exposure of approximately 60%, which might be related to the observed gastrointestinal toxicity. The main route of elimination of XR11576 is likely to be hepatic metabolism.

The purposes of the present phase I study were to determine the MTD of XR11576 administered orally on days 1–5 every 21 days, to establish the dose-limiting and other toxic effects, to describe the PK of XR11576, to document any antitumour effects and to establish a dose suitable for further phase II evaluation of activity of the compound.

**PATIENTS AND METHODS**

**Patient selection**

Patients with a cytologically or histologically confirmed diagnosis of a malignant solid tumour refractory to standard forms of therapy were eligible for this study, provided that they met the following criteria: age between 18 and 75 years; WHO performance status ≤ 1; estimated life expectancy ≥ 3 months; no previous anticancer therapy for at least 4 weeks; no major fluid effusions; no significant gastric or small intestine disease that might influence the absorption of the drug; and adequate haematopoietic (haemoglobin ≥ 5.2 mmol l$^{-1}$, absolute peripheral granulocyte count ≥ 2.0 × 10$^{11}$ l$^{-1}$ and platelet count ≥ 100 × 10$^{11}$ l$^{-1}$), hepatic (bilirubin ≤ the upper normal limit, and serum aspartate aminotransferase and alanine aminotransferase ≤ 3.0 times the upper normal limit) and renal (serum creatinine concentration ≤ the upper normal limit) functions. Patients with symptomatic brain or leptomeningeal metastases were excluded. Patients had to be able to swallow size 1 capsules. All patients gave written informed consent before study entry. The study was approved by the Institutions’ Medical Ethic Committees.

**Treatment and dose escalation**

XR11576 was supplied by Fulcrum Pharma Developments Ltd (Hemel Hempstaed, UK) as size 1 gelatin capsules comprising 5.0, 20.0, 60.0 and 120.0 mg of active drug and dibasic calcium phosphate anhydrous. The capsules were stored at room temperature (25°C or below). Capsules were taken once a day, with a glass of water after an overnight fasting of at least 2 h before breakfast. The daily dose of XR11576 was provided in separate boxes, each of which was clearly identifiable by the patient. Patients were instructed to record their daily amount of capsules taken, the time of administration and the timing in relation to breakfast. Compliance with the scheduled treatment was assessed at the end of each course, by counting the used and returned capsules of XR11576 in relation to the record kept by the patient for the given cycle. With the exception of the first and second courses, during which patients were hospitalised for PK sampling, patients were treated on an outpatient basis.

The starting dose of XR11576 was 30 mg day$^{-1}$, one out of three of the no observed adverse effect level and one out of 10 of the MTD in rat and dog. Since for most anticancer agents dosing according to body surface area does not reduce the interpatient variability in PKs, it was decided to use absolute doses of XR11576 and study the relation between oral clearance of XR11576 and the body surface area (Ratain, 1998). The total dose prescribed was rounded to the nearest 5 mg. At least three patients were entered at each dose level. Dose escalations between cohorts were based on the prior dose level’s toxicity and pharmacological data, allowing a dose escalation up to 100% (which was determined by the worst significant toxicity). Once ≥ grade 2 toxicity was observed in one patient, further dose escalation did not exceed 50%. The stopping dose was defined as the dose level that induced dose-limiting toxicity (DLT) during course 1 in ≥ 2/3 or ≥ 2/6 patients. Dose-limiting toxicities were defined as grade 4 granulocytopenia for 7 or more days, febrile neutropenia, platelets < 25.0 × 10$^{11}$ l$^{-1}$ and/or nonhaematological toxicity ≥ grade 3. Nausea and vomiting subsequently responding to antiemetic therapy were excluded from DLT. The relation with oral clearance of XR11576 and the body surface area (Ratain, 1998) was studied, in which involved sodium, potassium, calcium, urea, creatinine, uric acid, total protein, albumin, total bilirubin, alkaline phosphatase, γ-glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase and glucose, were performed, as were urinalysis, pregnancy test, relevant tumour markers, electrocardiogram and a chest X-ray. The electrocardiogram was also performed 2 and 24 h after the first drug administration in the first and second cycles. Weekly evaluations included history, physical examination, toxicity assessment according to the CTC criteria version 2.0, and serum chemistries. Complete blood count was...
determined twice weekly. Tumour evaluation was performed after every two courses according to the Response Evaluation Criteria in Solid Tumours (RECIST) (Therasse et al, 2000). Patients were taken off protocol at the onset of disease progression.

Sample collection and drug analysis

For PK analysis, 58 blood samples (~5 ml each) were obtained from an indwelling intravenous cannula and collected in vials containing lithium heparin as anticoagulant. The samples were taken immediately before dosing, 30 min and 1, 1.5, 2, 3, 4, 6, 8 and 10 h after administration of the drug on days 1 and 4 (or 5) of the first and second courses. Additional samples were taken immediately prior to dosing on days 2, 3, 4 and 5, and 24, 48, 72, 144 and 312 h after the dose administration on day 5, both in the first and second cycles. From the third cycle onwards, PK samples were taken prior to dosing on day 5 to measure the potential accumulation of XR11576.

All samples were centrifuged immediately after sampling at 3000 r.p.m. for 10 min at 4°C and the plasma was stored at −20°C or lower in polypropylene tubes in the dark until analysis. A total of four urine samples were also collected over a 24-h period; 0–4, 4–8, 8–12 and 12–24 h post-dosing on day 1 of the first cycle only. Of the total amount collected, a measured quantity of 10 ml was drawn off and stored at −80°C until analysis. Concentrations of XR11576 in plasma were determined according to a validated liquid chromatography-mass spectrometry detection method with liquid–liquid extraction at the Drug Metabolism and Pharmacokinetics Department of Quintiles Limited (Internal Report at Quintiles). The lower limit of quantitation was 5 ng ml⁻¹.

PK data analysis

The apparent terminal half-life (T½(Z)) of XR11576 was calculated as ln2/k, where k is the terminal elimination rate constant (expressed in h⁻¹). The peak plasma concentrations (Cmax) and the time to peak plasma concentration (Tmax) were determined from the experimental values. The areas under the plasma concentration–time curve (AUC) of XR11576 were estimated using the experimental values (trapezoidal rule) with extrapolation to infinity (AUC(0–∞)) using the apparent terminal rate constant, defined as the slope of the final three to four data points of the log-linear concentration–time plot. The total body clearance (CL) was calculated as the ratio between the administered dose and the AUC(0–∞). The extent of accumulation (RA) in plasma was calculated from AUC(0–∞) (days 4 or 5)/AUC(0–∞) (day 1). The fraction of the administered dose (F) excreted in urine and the cumulative amount of XR11576 excreted in urine (Ae) was determined. PK data analysis was carried out using a noncompartmental analysis approach with the aid of WinNonlin Version Pron 4.0.1 (Pharsight, Cary NC 27511).

Statistical analysis  A nonlinear power model was used to assess dose proportionality separately for each day during cycles 1 and 2. Statistical analyses were performed using SAS version 8.1.

RESULTS

Between January 2002 and April 2003, 22 patients, whose main characteristics are listed in Table 1, were enrolled onto the study at two centres. All patients were eligible. One patient, entered at the 120 mg day⁻¹ dose level, did not receive any medication due to deterioration of his condition prior to study start. The majority of the patients were either asymptomatic or had only mild symptoms at study entry. Patients were pretreated with a median of two prior chemotherapy regimens (range 1–6). The total number of assessable courses was 47. The median number of courses per patient was 2 (range 1–10). Dose levels studied were 30, 60, 120, 180 and 150 mg day⁻¹ XR11576 administered orally on days 1–5, with courses repeated once every 21 days. Toxicity did not necessitate dose reductions. However, three patients went off study because of the toxicity experienced at the 120 (1 patient) and 180 mg day⁻¹ (2 patients) dose levels. In the absence of DLT, the dose of XR11576 was escalated from 30 to 180 mg day⁻¹. Since all previously entered patients on the 120 mg day⁻¹ dose level had experienced grade 2 nausea/vomiting during treatment, which could not be ameliorated by the use of prokinetic antiemetics, it was decided to introduce the use of prophylactic 5HT3 antagonists at the 180 mg day⁻¹ dose level. At the 180 mg day⁻¹ dose level, DLT was encountered in two of three patients. One of the patients experienced fatigue grade 3 in the first treatment course. The second patient considered to have DLT experienced in her first cycle grade 2 diarrhoea, vomiting and fatigue. For a coincident upper airway infection, she was treated with antibiotics. In her second cycle, she experienced diarrhoea grade 4 in combination with nausea grade 1, fatigue grade 2, hypotension grade 3 and electrolyte disturbances grade 3. Although the diarrhoea might have been aggravated by the previous use of antibiotics, the event was considered study drug related. In spite of the fact that the DLT in this second patient was observed in the second cycle, it was decided that the dose of 180 mg day⁻¹ was not feasible. At this point, the previous dose level of 120 mg day⁻¹ was expanded. The first two additional patients did not encounter DLT. However, despite the prophylactic use of 5HT3 antagonists, they experienced nausea/vomiting grade 2. Therefore, the next three patients at the 120 mg day⁻¹ dose level received a combination of 5HT3 antagonists and dexamethasone prophylactically, rendering the level of nausea and vomiting acceptable. One of the additional patients at this dose level experienced diarrhoea grade 2. Therefore, the next three patients at the 120 mg day⁻¹ dose level received a combination of 5HT3 antagonists and dexamethasone prophylactically, rendering the level of nausea and vomiting acceptable. One of the additional patients at this dose level experienced diarrhoea grade 2. Therefore, the next three patients at the 120 mg day⁻¹ dose level received a combination of 5HT3 antagonists and dexamethasone prophylactically, rendering the level of nausea and vomiting acceptable.
of a tapering dose of dexamethasone in combination with metoclopramide during the 3 days following therapy. On the basis of these results, and in view of XR11576’s development as an oral therapy, the 150 mg day\(^{-1}\) dose level was not considered feasible and the recommended dose of XR11576 for further studies is 120 mg day\(^{-1}\) administered on days 1–5 every 3 weeks.

**Tolerability**

Diarrhoea and fatigue were the principal DLTs and were observed both at the 180 and 150 mg day\(^{-1}\) dose level. They also constituted the most common nonhaematological effects of XR11576 together with nausea and vomiting (Tables 2 and 3). Both the incidence and severity of diarrhoea increased with the dose of XR11576 administered. The median day of onset was day 5 (range 1–15 days), with a median duration of 4 days (range, 1–14 days). In most patients, the diarrhoea was self-limiting. Five patients required treatment with loperamide. Patients treated at the lower dose levels did not routinely receive antiemetic premedication with their first dose. However, once established, nausea and vomiting were difficult to treat. Therefore, it was decided to introduce prophylactic treatment with 5HT\(_3\) antagonists at the 180 mg day\(^{-1}\) dose level. Since single-agent treatment with 5HT\(_3\) antagonists could not prevent nausea or vomiting, it was decided to combine the 5HT\(_3\) antagonists with dexamethasone for the additional patients treated at the 120 mg dose level. Although the treatment with XR11576 was better tolerated, all patients experienced mild to moderate nausea. Only one patient developed grade 1 alopecia during treatment with XR11576.

Overall, the haematological toxicity was mild (Tables 2 and 3). Only one patient, who was heavily pretreated, experienced grade 4 neutropenia, which was not complicated by fever. In the patient who received 10 cycles, there was no evidence of cumulative haematological toxicity. Thrombocytopenia was limited to grade 1 and 2, and only observed in three patients, two of whom were treated at the highest dose level. In seven patients grade 1 anaemia was encountered, in four patients grade 2 anaemia. Anaemia did not seem to be dose related.

Electrocardiograms were performed prior to treatment and following first drug administration. No significant abnormalities in ECG tracings were observed. No clinical signs of impaired cardiac function were observed in any of the patients treated.

**Antitumour activity**

No objective responses were observed. Four patients experienced stabilisation of their disease (melanoma, cervical cancer and parotid cancer) for a median duration of 12 weeks (range 12–30 weeks).

**Pharmacokinetics**

Full kinetic data were obtained on days 1 and 4 from 21 patients following the administration of XR11576.

The plasma concentration–time profiles of XR11576 were similar for all patients studied, with a representative example shown in Figure 2. Maximum peak drug levels occurred at 3.69 ± 0.79 h post dose and declined with a mean terminal half-life of up to 70 h. Inspection of the scatterplots of dose vs either AUC\(_{0-\infty}\) (Figure 3A) or \(C_{\text{max}}\) (Figure 3B) for XR11576 revealed an increase of both parameters with the dose level administered.

![Figure 2](image)

**Table 2** Toxicity in the first cycle according to NCI-CTC version 2.0

| Dose (mg day\(^{-1}\)) | No. pts per cycle | WBC | ANC | Plt | Nausea | Vomiting | Fatigue | Diarrhoea |
|------------------------|-------------------|-----|-----|-----|--------|----------|---------|-----------|
| 30                     | 3/13              | 1   | 2   | 3   | 4      | 1        | 2       | 3         |
| 60                     | 4/10              | 1   | 2   | 3   | 4      | 1        | 2       | 3         |
| 120                    | 8/16              | 1   | 2   | 3   | 4      | 1        | 2       | 3         |
| 180                    | 3/5               | 1   | 2   | 3   | 4      | 1        | 2       | 3         |
| 150                    | 3/5               | 1   | 2   | 3   | 4      | 1        | 2       | 3         |

No. pts = number of patients; Plt = platelets; DLT = dose-limiting toxicity.

**Table 3** Worse toxicity per cycle for all cycles according to NCI-CTC version 2.0

| Dose (mg day\(^{-1}\)) | No. pts per cycle | WBC | ANC | Plt | Nausea | Vomiting | Diarrhoea |
|------------------------|-------------------|-----|-----|-----|--------|----------|-----------|
| 30                     | 3/13              | 1   | 2   | 3   | 4      | 1        | 2         |
| 60                     | 4/10              | 1   | 2   | 3   | 4      | 1        | 2         |
| 120                    | 8/16              | 1   | 2   | 3   | 4      | 1        | 2         |
| 180                    | 3/5               | 1   | 2   | 3   | 4      | 1        | 2         |
| 150                    | 3/5               | 1   | 2   | 3   | 4      | 1        | 2         |

No. pts = number of patients; Plt = platelets.
The long half-life relative to the dosing interval resulted in accumulation in plasma of XR11576, such that exposure was approximately two-fold higher by the last day of dosing. The intrapatient variability was assessed by comparing the AUC0–24h values on days 1 and 4 during cycle 1 with the corresponding values during cycle 2. In general, systemic exposure during cycle 1 was not appreciably different from that observed during cycle 2, with average AUC0–24h ratios ranging from 0.9 to 1.6. The interpatient variability in the observed PKs was large, with coefficients of variation in AUC values as high as > 100%.

Over the dose levels studied, the systemic exposure to XR11576 increased with increasing dose. Overall, systemic exposure increased in a greater than dose-proportional manner (Figure 3). The mean PK parameters determined using a noncompartmental analysis are listed in Table 4. In all patients, the PKs of XR11576 were also determined in the second cycle. There were no significant differences between PK parameters derived from paired

**Figure 3** Relationship between AUC (A) and \(C_{\text{max}}\) (B) on day 1 of the first cycle of XR11576 as a function of dose administered per day.

**Figure 4** Relationship between the absolute apparent CL/F (calculated by dividing the absolute administered oral dose of XR11576 by the AUC of XR11576).

**Table 4** Summary of the pharmacokinetics of XR11576 during the first treatment course

| Dose level (mg day\(^{-1}\)) | \(N\) | \(\text{AUC}_{0-4}\) (ng h ml\(^{-1}\)) | \(\text{AUC}_{0-24h}\) (ng h ml\(^{-1}\)) | \(\text{C}_{\text{max}}\) (ng ml\(^{-1}\)) | \(T_{\text{max}}\) (h) | \(T_{1/2}\) (h) | \(R_0\) |
|-----------------------------|-----|---------------------------------|---------------------------------|----------------------------|----------------|----------------|------|
| 30                          | 3   | 36.2                            | 500                             | 8.07                       | 2.5            | 5.53           | 1.56 |
|                             |     | c\% 83.0                        | 88.2                            | 53.8                       | 34.6           | 75.4           | 17.9 |
| 60                          | 4   | Mean 178                        | 517                             | 21.7                       | 3.50           | 68.8           | 1.87 |
|                             |     | c\% 98.3                        | 26.3                            | 605                        | 16.5           | 70.4           | 30.2 |
| 120                         | 8   | Mean 329                        | 535                             | 41.1                       | 3.75           | 31.2           | 1.93 |
|                             |     | c\% 109                         | 94                              | 90.4                       | 27.6           | 162            | 78.6 |
| 180                         | 3   | Mean 970                        | 1812                            | 112                        | 4.67           | NC             | 1.34 |
|                             |     | c\% 45.7                        | 27.6                            | 63.4                       | 24.7           | NC             | 7.1  |
| 150                         | 3   | Mean 1708                       | 2236                            | 167                        | 4.00           | NC             | 1.53 |
|                             |     | c\% 9.89                        | 7.78                            | 40.9                       | 0              | NC             | 5.9  |

\(N\) = number of patients; c\% = coefficient of variation; \(\text{AUC}\) = area under the concentration–time curve; \(\text{C}_{\text{max}}\) = peak plasma level; \(T_{\text{max}}\) = time to maximal concentration; \(T_{1/2}\) = terminal elimination half-life; \(R_0\) = ratio of accumulation; NC = not calculated as terminal exponential phase could not be unambiguously identified.
Although nausea and vomiting were not considered as a DLT, all patients at the recommended dose level of 120 mg day$^{-1}$ experienced nausea and/or vomiting grade 1–2, despite a vigorous prophylactic antiemetic regimen. With the exception of the first two dose levels, nausea and vomiting started within the first 2 days of treatment and tended to have a more protracted course with increasing dose (median duration 2 days (range 1–5) at 30 mg to a median duration of 6 days (range 1–20) at dose level 180 mg). Acknowledging that this is a major drawback for an oral formulation, an alternative regimen employing day 1 and 8 administration every 21 days is being evaluated with the assumption that such a regimen would require a more limited use of antiemetics. If this schedule results in a higher dose intensity and more manageable gastrointestinal side effects, it will be considered for phase II testing.

Haematological toxicity was mild in this study and not clearly dose- or exposure-related. This is in contrast to the haematological toxicity observed with most topoisomerase I inhibitors. The limited haematological toxicity might be related to the relatively limited systemic exposure to the drug, although the AUC values measured from the dose level of 120 mg onwards were within the range of AUC values associated with preclinical activity.

In the present study, the systemic exposure to XR11576 rose more than proportional to increasing dose. Oral bioavailability studies have not been performed because of lack of an intravenous formulation of the drug. XR11576 was administered at fixed doses during the study. Using linear regression analysis, XR11576 oral clearance was not significantly related to patient body surface area, confirming that the application of dosing per body surface area would not have Optimised dosing of this agent.

In this study, the DLTs of XR11576 were diarrhoea and fatigue. The recommended dose for phase II studies of XR11576 is 120 mg administered orally, on days 1–5 every 21 days. Alternative regimens are currently being explored.

REFERENCES

Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD (1997) Phase I and pharmacologic study of oral topotecan administered twice daily for 21–days to adult patients with solid tumors. J Clin Oncol 15: 1087–1093

De Jonge MJA, Punt CJA, Gelderblom JA, Loos WJ, Van Beurden V, Planting ASTh, Van der Burg MEL, Van Maanen LWGM, Dallaire BK, Verweij J, Wagener DJT, Sparreboom A (1999) Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol 17: 2219–2226

Denny WA, Baguley B (2003) Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 3: 339–353

Di Nicolantonio F, Prin A, Mills L, Knight LA, Charlton PA, Cree IA (2002) The effect of MDR1 on the ex vivo activity of XR5944 (MLN944) and XR11576 (MLN576), two novel DNA targeting agents. Eur J Cancer 38: 32 Eng W-K, Faucette L, Johnson RK, Sterlings LA (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755–760

Etevant C, Kruuzinski A, Barret JM, Perrin D, Van Hille B, Guminisik Y, Hill BT (2000) F 11782, a dual inhibitor of topoisomerase I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, etoposide, lurtacrubin and TAT-103. Cancer Chemother Pharmacol 46: 101–113

Ferguson PJ, Fisher MH, Stephenson J, Li D, Zhou B, Cheng Y (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956–5964

Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, Van der Burg ME, Rodriguez GI, Loos WJ, Van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J (1998) Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 4: 1153–1158

Heck MMS, Hittkeelman WN, Earmshaw WC (1988) Differential expression of DNA topoisomerase I and II during eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086–1090

Hsiang Y-H, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082

Jobson A, Willmore E, Tilby M, Mistry P, Charlton P, Austin C (2002) Characterisation of the roles of topoisomerase I and II in the mechanism of action of novel antitumour agents XR11576 (MLN576) and XR9494 (MLN944). Eur J Cancer 38: 31

Leufve D, Riou J-F, Ahomadegbe JC, Zhou D, Benard J, Riou G (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and the acidic glutathione S transferase. Biochem Pharmacol 41: 1967–1979

Lewis LJ, Charlton PA, Mistry P, Thomas H, Coyle HM (2003) Cellular characterization and differentiation of XR9494 (MLN944) from XR11576 (MLN576), two novel DNA targeting agents. Proc AACR 44: 406 Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilkly SL, Ratain MJ (1998) Phase I clinical and pharmacokinetic study of oral 9-amino-camptothecin (NSC-603071). Cancer Chemother Pharmacol 42: 84–87

Mistry P, Stewart AJ, Dangerfield W, Brec M, Liddle C, Bootle D, Kolber L, Laurie D, Denny WA, Baguley B, Charlton PA (2002) In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anti-cancer Drugs 13: 15–28

Natelson EA, Giovannella BC, Verschaeren CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS (1996) Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224–230

Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R (1999) Phase I trial of topotecan (RP 66375) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs 10: 869–894
Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit. *J Clin Oncol* 16: 2297–2298

Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. *Semin Oncol* 8: 837–855

Soepenberg O, Dumez H, Verweij J, Selleslach J, Ter Steeg J, Assadourian S, Boeuf C, Lefebvre P, Sparreboom A, van Oostrum AT (2002) Phase I and pharmacokinetic study of oral irinotecan (CPT-11) on a daily-times 5 schedule every 3 weeks in combination with evaluation of food effect. *Eur J Cancer* 38: S46

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oostrum AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment of solid tumours. *J Natl Cancer Inst* 92: 205–216

Twelves CJ, Gardner C, Flavin A, Sludden J, Dennis I, de Bono J, Beals P, Vasey P, Hutchison C, Macham MA, Rodriguez A, Judson I, Bleeheen NM (1999) Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC phase I/II Committee. *Br J Cancer* 80: 1786–1791

Verschraegen CF, Natelson EA, Giovannella BC (1998) A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. *Anti-Cancer Drugs* 9: 36–44

Wang S, Miller W, Milton J, Vicker N, Stewart A, Charlton P, Mistry P, Hardick D, Denny WA (2002) Structure–activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576. *Bioorg Med Chem Lett* 12: 415–418